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VP16 is a virion phosphoprotein of herpes simplex virus and a transcriptional activator of the viral immediate-early (IE) genes. We identified
four novel VP16 phosphorylation sites (Ser18, Ser353, Ser411, and Ser452) at late times in infection but found no evidence of phosphorylation of
Ser375, a residue reportedly phosphorylated when VP16 is expressed from a transfected plasmid. A virus carrying a Ser375Ala mutation of VP16
was viable in cell culture but with a slow growth rate. The association of the mutant VP16 protein with IE gene promoters and subsequent IE gene
expression was markedly reduced during infection, consistent with prior transfection and in vitro results. Surprisingly, the association of Oct-1
with IE promoters was also diminished during infection by the mutant strain. We propose that Ser375 is important for the interaction of VP16 with
Oct-1, and that the interaction is required to enable both proteins to bind to IE promoters.
D 2005 Elsevier Inc. All rights reserved.Keywords: Transcriptional activation; Vmw65; a-Trans-inducing factor; Oct-1; Immediate-early gene; Chromatin immunoprecipitationIntroduction
The virion protein VP16 of herpes simplex virus type 1
(HSV-1) serves multiple functions during lytic infection. VP16
(also known as Vmw65 and a-TIF) is most prominently known
as a transcriptional activator of the viral immediate-early (IE)
genes (O’Hare, 1993; Triezenberg, 1995). Two types of cis-
acting elements in IE promoters mediate activation by VP16. A
motif rich in guanosine and adenosine nucleotides binds the host
heterodimeric protein GABP (LaMarco and McKnight, 1989;
Triezenberg et al., 1988a, 1988b), but no direct interaction of
GABPwith VP16 has yet been demonstrated. A second element,
with a consensus sequence of TAATGARAT (where R repre-0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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California, Berkeley, CA 94720, USA.sents either purine nucleotide), is bound by a protein complex
comprising VP16 and two cellular proteins, the DNA binding
protein Oct-1 and an accessory protein HCF-1 (Gerster and
Roeder, 1988; Katan et al., 1990; Kristie et al., 1989; O’Hare and
Goding, 1988; Xiao and Capone, 1990). VP16 interacts directly
with both Oct-1 and HCF-1 through adjacent regions in the core
domain of VP16. The interaction with Oct-1 is mediated by a
region spanning amino acids (aa) 370–390 (Greaves and
O’Hare, 1990; Lai and Herr, 1997) of VP16, and the interaction
with HCF-1 is mediated by VP16 residues 355–370 (Lai and
Herr, 1997; Shaw et al., 1995; Simmen et al., 1997; Wu et al.,
1994). Although crystallographic and small-angle X-ray scat-
tering structures of the core domain (residues 49–410) of VP16
have been described (Grossmann et al., 2001; Liu et al., 1999),
the region spanning these two protein interaction motifs was
disordered in that structure.
The transcriptional activation domain (TAD) of VP16
resides within the carboxyl terminal residues 411–490
(Greaves and O’Hare, 1989; Triezenberg et al., 1988a,
1988b; Werstuck and Capone, 1989). Within that domain are6) 468 – 481
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which can function to activate expression of target genes
(Regier et al., 1993; Tal-Singer et al., 1999; Walker et al.,
1993). Although each of these subregions is rich in acidic
amino acids, mutational analyses have demonstrated that bulky
hydrophobic residues are particularly critical to their transcrip-
tional function (Cress and Triezenberg, 1991b; Regier et al.,
1993; Sullivan et al., 1998). The TAD of VP16 can interact
with a number of basal transcription factors including TBP and
TAF9 from TFIID, TFIIA, TFIIB, and TFIIH (Triezenberg,
1995). Furthermore, the VP16 TAD can interact genetically
and physically with coactivator protein complexes including
the Mediator complex of the RNA polymerase II holoenzyme
(Mittler et al., 2003; Yang et al., 2004), histone acetyltrans-
ferases (Berger et al., 1992; Memedula and Belmont, 2003;
Utley et al., 1998; Wang et al., 2000), and ATP-dependent
remodeling enzymes homologous to the yeast SWI/SNF
complex (Memedula and Belmont, 2003; Neely et al., 1999).
Recent evidence directly implicates the VP16 AD in recruiting
the mammalian histone acetyltransferases p300 and CBP and
the remodeling enzymes BRG1 and hBRM to viral IE gene
promoters during lytic infection (Herrera and Triezenberg,
2004).
In addition to its well-known transcriptional function, VP16
also plays other roles in the infectious cycle of HSV-1. VP16 is
an abundant component of the tegument compartment of the
virion. An HSV-1 strain from which the entire VP16 gene has
been deleted is not viable in non-complementing cells, an
indication that VP16 is an essential protein for virion assembly
(Weinheimer et al., 1992). A temperature-sensitive mutant of
HSV-2 has a conditional defect in virion stability that maps to
the VP16 gene (Moss, 1989). Temperature-sensitive mutants of
HSV-1 have also been constructed by replacing specific
cysteine residues of VP16 with glycine (Poon and Roizman,
1995), resulting in defects in virion maturation. In contrast,
deletion of only the VP16 activation domain resulted in
efficient production of virions that are nonetheless poorly
infectious because of the reduced expression of IE genes
(Smiley and Duncan, 1997; Tal-Singer et al., 1999). VP16
interacts with other virion proteins including the vhs protein,
which induces degradation of mRNAs in infected cells (Strand
et al., 2004). Several lines of evidence suggest that this activity
is likely regulated at least in part by interaction with VP16
(Elliott et al., 1995; Knez et al., 2003; Lam et al., 1996;
Smibert et al., 1994; Strand and Leib, 2004). VP16 also
interacts with another virion protein, VP22 (Elliott et al., 1995),
likely through sequences within the VP16 TAD, but the
relevance of this interaction in the context of lytic infection
has not been defined.
VP16 has long been known as a phosphoprotein in infected
cells and in virions (Gibson and Roizman, 1974; Lemaster and
Roizman, 1980), although the regulatory role (if any) of this
modification has yet to be defined. VP16 phosphorylation upon
entry into the infected cell may facilitate its dissociation from
the virion and its intracellular localization (Morrison et al.,
1998a, 1998b). One predominant phosphorylation site, Ser375,
was identified in VP16 protein expressed from a transfectedplasmid (O’Reilly et al., 1997). This site is particularly
interesting because it lies within the region implicated in
binding to Oct-1. Moreover, mutation of Ser375 to alanine
disrupted interaction with Oct-1 and thereby ablated the ability
of VP16 to activate expression of reporter genes. However,
whether phosphorylation per se modifies the interaction of
VP16 with Oct-1 has not been definitively established, nor was
this site of phosphorylation confirmed in infected cell lysates.
To further advance our understanding of VP16 phosphor-
ylation and the potential regulatory implications thereof, we
mapped phosphorylation sites in VP16 protein isolated from
cells at late times of infection. We identified four phosphor-
ylated Ser residues but saw no evidence of phosphorylation of
Ser375. A recombinant virus bearing a Ser375Ala mutation in
VP16 was viable but showed diminished growth kinetics
following either high or low-multiplicity infections. This defect
corresponds to a significant reduction in IE gene expression
during infections and to a diminished presence of both VP16
and Oct-1 proteins on IE gene promoters. These results support
a model in which Ser375 is essential for Oct-1 interaction and
IE gene activation but do not directly implicate phosphoryla-
tion in regulating that activity.
Results
Sites of VP16 phosphorylation at late times post-infection
To establish the phosphorylation status of VP16 in infected
cells, HeLa cells were infected with wild type HSV-1 (KOS) at
a multiplicity of infection (moi) of 5. [32P]-orthophosphate was
added to the culture medium at 1.5 h post-infection (hpi).
Infected cells was harvested and lysed at 8 hpi. VP16 was
isolated by immunoprecipitation (IP) using the monoclonal
antibody LP1, which recognizes an epitope near the amino
terminus of VP16. The proteins in the IP pellets were separated
by SDS-PAGE, and radiolabeled proteins were visualized by
autoradiography. A [32P]-labeled band with an apparent
molecular weight of 65 kDa was observed for samples from
the IP pellet (Fig. 1B). Lysates of non-infected cells, processed
through a parallel radiolabeling and IP protocol, did not display
a comparable band (data not shown). The radiolabeled species
co-migrated with VP16 visualized by immunoblotting (Fig.
1C). These results confirm the presence of phosphorylated
VP16 in infected cell lysates. Samples of immunoprecipitated
material from virions harvested at 14 hpi and purified by
density gradient centrifugation showed a comparable radiola-
beled band (data not shown), indicating that the VP16 protein
in virions is also phosphorylated.
Two viral strains encoding truncation mutants of VP16 (Tal-
Singer et al., 1999) were used initially to map the location of
the phosphorylation site(s). The RP3 strain encodes a VP16
protein truncated at aa 456 (Fig. 1A) and thus lacks the
carboxyl terminal half of the transcriptional activation domain.
The RP5 strain encodes a protein truncated at residue 412 and
thus lacks the entire activation domain. Both of these strains
are viable without complementation, but RP5 is less efficient at
initiating infection (Tal-Singer et al., 1999). Cells infected with
Fig. 1. Mapping VP16 phosphorylation sites using deletion mutants and peptide
mapping. (A) Schematic diagram of VP16. The two subregions of the C-
terminal activation domain are denoted by hatching. Regions implicated in
interaction with Oct-1 and HCF-1 are indicated by black and grey boxes,
respectively. The four lysine residues in VP16 (K) and some of the serine
residues (S) are indicated. Open arrows mark the truncations of the VP16 open
reading frame in the viral strains RP3 and RP5. (B) Autoradiogram of material
precipitated using a VP16-specific monoclonal antibody (LP1) from HeLa cells
infected by virus strains KOS, RP3 and RP5 and radiolabeled with [32P]-
orthophosphate from 1.5 to 8 h post-infection. The relative positions of protein
molecular weight standards following separation on a 10% SDS-PAGE gel are
indicated (in kDa). (C) Immunoblot of a gel in parallel to that shown in panel B,
probed with a VP16-specific polyclonal antibody (C8). (D) Autoradiogram of
radiolabeled VP16 fragments following digestion by lysyl endopeptidase
(LysC), separated on a 16% polyacrylamide gel. (E) Autoradiogram of
radiolabeled VP16 fragments following digestion by trypsin and separation
on a 16% polyacrylamide gel.
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lysates were harvested at 8 hpi and were immunoprecipitated
using the VP16-specific antibody LP1. Infection by RP3 and
RP5 gave rise to a phosphorylated species that corresponded to
the expected apparent molecular weight of the truncated
proteins (58 kDa and 52 kDa respectively; Fig. 1B). The
identity of the labeled species was confirmed by subsequent
immunoblotting of the labeled extract (Fig. 1C). These results
indicate that one or more phosphorylation sites exist within the
N-terminal 412 amino acids of VP16 but do not preclude the
possibility of additional phosphorylation sites within the C-
terminal 88 residues. Moreover, these results indicate that the
activation domain is not necessary for phosphorylation of
VP16.
To further define the site or sites of phosphorylation, [32P]-
labeled VP16 was immunoprecipitated from lysates of cells
infected with KOS, RP3 and RP5 and then digested with
lysylendopeptidase (LysC). Given that the four lysine residues
in the VP16 protein sequence are located at positions 29, 103,343 and 370 (Fig. 1A), complete digestion with LysC is
expected to produce five fragments of approximate molecular
weight 3.0 kDa (aa 1–29), 8.0 kDa (aa 30–103), 28 kDa (aa
104–343), 3.1 kDa (aa 344–370) and 13 kDa (aa 371–490).
The VP16 proteins from strains RP3 and RP5 differ from full-
length VP16 only in the latter fragment. Digestion of the
sample from KOS-infected cells yielded a single predominant
phosphorylated species migrating with an apparent molecular
weight of 17 kDa (Fig. 1D). The truncated VP16 from RP3
gave rise to a single radioactive band that migrated at 11 kDa.
RP5 gave rise to a prominent band migrating at 5.4 kDa. Each
lane contains a faint band with a mobility corresponding to a
protein of approximately 6.0 kDa. The predominant bands in
both the RP3 and the RP5 samples migrated as would be
predicted for the carboxyl terminal fragment of the LysC
digestion. These observations indicate that the major phos-
phorylation sites of VP16 are present within the C-terminal
fragment, with at least one prominent site of VP16 phosphor-
ylation within the fragment spanning aa 371–412 (as observed
for RP5). Serine residues are present within this fragment at
positions 375, 400 and 411 (Fig. 1A). No radiolabeled bands
were present that correspond to the 28-kDa and 8-kDa
fragments expected from LysC digestions, which are common
to the three forms of VP16 tested. This indicates that
phosphorylation is not present in VP16 between amino acids
30 and 343. The identity of the fragment giving rise to the
relatively weak signal at 6.0 kDa is ambiguous; the two
smallest products expected from LysC digestion are 3.0 kDa
(aa 1–29) and 3.1 kDa (aa 344–370), and the mobility of such
small polypeptides can vary significantly in SDS-PAGE gels.
To further define the positions at which VP16 is phosphor-
ylated, the radiolabeled and immunoprecipitated VP16 protein
was digested with trypsin. Complete digestion of VP16 with
trypsin is expected to yield some 43 fragments, all but one with
molecular weights less than 4 kDa. The exception is the C-
terminal fragment of 8.5 kDa, which includes the acidic
transcriptional activation domain. Trypsin digestion of VP16
immunoprecipitated from KOS-infected HeLa cells gave rise to
a major phosphorylated species that migrated with apparent
molecular weight of 11 kDa and a second labeled fragment of
approximately 12 kDa (Fig. 1E). These bands likely corre-
spond to the C-terminal fragment (410–490) and a partial
digestion product that includes an additional 11 residues. This
result implies that one or more of the Ser residues C-terminal to
amino acid 410 (i.e., Ser411, 419, 452 and 462) are
phosphorylated at late times in infected cells. A fainter band
with mobility corresponding to approximately 5 kDa is also
apparent in this sample; the identity of the peptide that this
band represents is uncertain.
To determine the phosphoamino acid complement of VP16,
[32P]-labeled protein was immunoprecipitated from HeLa cells
infected with KOS, RP3 or RP5. The proteins in the IP pellet
were acid hydrolyzed, and the component amino acids were
resolved by thin layer electrophoresis (Fig. 2). In all three
cases, a radioactive species was found which co-migrated with
the phosphoserine standard. No labeled species were found to
correlate with the phosphothreonine or phosphotyrosine
Fig. 2. Phosphoamino acid analysis of VP16 proteins radiolabeled from 1.5 to
8 h following infection with virus strains KOS, RP3 and RP5. The VP16
protein was isolated from infected cell lysates by immunoprecipitation with
monoclonal antibody LP1 followed by SDS-PAGE. Proteins were transferred to
a PVDF membrane, and the band corresponding to VP16 was excised. Proteins
were hydrolyzed in 6 N HCl for 1 h at 100 -C. Samples were mixed with
unlabeled phosphoserine, phosphothreonine and phosphotyrosine standards and
separated by thin-layer electrophoresis on a cellulose plate at pH 2.5.
Phosphoamino acid standards were visualized using ninhydrin (dotted circles),
and radiolabeled amino acids were detected by autoradiography.
Table 1
Phosphorylated and non-phosphorylated peptides spanning Ser18, Ser353,
Ser375 or Ser452 as detected by MS/MS
Residue Coverage Representative spectra (peptide)a
Serine 18 4–29 LVDELFADMDADGASPPPPRPAGGPK
5–29 VDELFADMDADGASPPPPRPAGGPK
5–29 VDELFADMDADGASPPPPRPAGGPK
6–29 DELFADMDADGASPPPPRPAGGPK
Serine 353 342–360 AKLDSYSSFTTSPSEAVMR
344–360 LDSYSSFTTSPSEAVMR
344–360 LDSYSSFTTSPSEAVMR
345–360 DSYSSFTTSPSEAVMR
348–360 SSFTTSPSEAVMR
351–359 TTSPSEAVM
Serine 375 369–398 TKNNYGSTIEGLLDLPDDDAPEEAGLAAPR
369–401 TKNNYGSTIEGLLDLPDDDAPEEAGLAAPRLSF
371–398 NNYGSTIEGLLDLPDDDAPEEAGLAAPR
372–398 NYGSTIEGLLDLPDDDAPEEAGLAAPR
374–401 GSTIEGLLDLPDDDAPEEAGLAAPRLSF
Serine 452 445–460 DMLGDGDSPGPGFTPH
449–460 DGDSPGPGFTPH
449–460 DGDSPGPGFTPH
a Boldface underlined S indicates phosphorylation of corresponding serine.
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or threonine residues are phosphorylated in VP16 derived from
late stages of infection of HeLa cells.
Mass spectrometric analysis of phosphorylated peptides
The VP16 phosphorylation sites were mapped more
precisely by proteolytic digestion and mass spectrometry.
Non-radiolabeled VP16 was purified by immunoprecipitation
from 109 HeLa cells infected with wild-type virus. The protein
was eluted from the immunoprecipitation pellet at high pH, and
the resulting eluate was separated on a 10% SDS-PAGE gel.
The gel was stained with Coomassie Blue, and the band
corresponding to VP16 was excised, washed in acetonitrile,
dried and frozen at 80 -C. Separate samples were digested
with trypsin, chymotrypsin and endopeptidase AspN and
subjected to microcapillary HPLC coupled with tandem mass
spectrometry (ALC/MS/MS).
A summary of the results from all digestions is given in Fig.
3 and Table 1. Fragments spanning approximately 79% of the
VP16 protein were observed in the MS/MS spectra (Fig. 3,
bold and underlined type). MS/MS spectra were consistent
with the presence of both phosphorylated and the unpho-
sphorylated peptides encompassing Ser18, Ser353 and Ser452Fig. 3. Peptide sequences identified following LC-MS/MS analysis of VP16 protein
immunoprecipitation and SDS-PAGE and then digested with trypsin or endoprote
underlined type indicates residues within peptide fragments identified following ALC
indicates Ser375, for which no phosphorylation was observed. A hatch (#) indica
experiments but not confirmed by ALC-MS/MS.(Table 1). Ser18 and Ser353 reside in the two smallest LysC
fragments that may have escaped detection on our SDS-PAGE
gels (Fig. 1). No evidence was found for phosphorylation at
Ser44, Ser51, Ser90, Ser106, Ser110, Ser154, Ser167, Ser309
and Ser333, consistent with the absence of radiolabeling in the
LysC fragments in which these amino acids reside. Only
spectra consistent with absence of phosphorylation were
observed for Ser346, Ser348, Ser349 or Ser355; these residues
all fall within one of the small LysC fragments. Six serine
residues were not covered by fragments observed by MS. Four
of these six (Ser72, Ser177, Ser186 and Ser262) are almost
certainly unphosphorylated, since they reside in LysC frag-
ments that were not radiolabeled. The remaining two, Ser411
and Ser419 both reside within the [32P]-labeled carboxyterm-
inal trypsin fragment (aa 411–490). Their phosphorylation
status could not be definitively determined by the available
peptide mapping and MS data.
No evidence of phosphorylation at Ser375 was found. All
five spectra for peptides encompassing this serine correspond
to the unphosphorylated form (Table 1). To explore this
question more thoroughly, the analysis was repeated using
targeted ion tandem mass spectrometry. In this method,s isolated at 8 h post-infection with HSV-1 strain KOS. VP16 was isolated by
inase AspN. The entire VP16 amino acid sequence is shown. Boldface and
-MS/MS. Asterisks indicate Ser residues found to be phosphorylated. A caret (^)
tes Ser411, the phosphorylation of which was implicated by peptide mapping
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non-phosphorylated masses of a particular digestion were
selected in the first dimension MS and then subjected to
fragmentation and sequencing by the second dimension MS.
Although this more focused analysis should increase the
likelihood of detecting low-abundance species, no phosphor-
ylated fragments corresponding to phosphorylation at Ser375
were observed (data not shown).
Mutation of Ser375 affects IE gene expression and viral growth
The results described in the preceding paragraphs indicate
that although proteolytic fragments encompassing Ser375 can
be phosphorylated, no phosphorylation of that residue itself is
evident in mass spectra. However, this site had previously been
shown to be critical for the interaction of VP16 with Oct-1
(Greaves and O’Hare, 1990; Lai and Herr, 1997; O’Reilly et
al., 1997) in vitro and for transcriptional activation in
transfected cells. To probe the role of Ser375 in the function
of VP16 during infection by HSV-1, a virus strain (designated
SJO2) was generated in which codon 375 of VP16 was altered
to specify alanine rather than serine. The presence of the
mutation in the recombinant viral genome was confirmed by
sequencing a PCR product spanning the site of interest
amplified from the viral DNA. Southern blotting with a probe
spanning the open reading frame and parts of the 3V- and 5V-
UTR confirmed that the mutant VP16 gene had been inserted
into the native VP16 locus (data not shown).
To determine whether the Ser375Ala mutation affected the
phosphorylation of VP16, a radiolabeled immunoprecipitate
from HeLa cells infected with SJO2 was compared to that from
KOS-infected cells. The autoradiogram in Fig. 4A reveals in
both samples a phosphorylated band at 65 kDa, corresponding
to the expected size for VP16 as detected in the immunoblot
(Fig. 4B). The intensity of the signal is comparable in the twoFig. 4. Phosphorylation of a Ser375Ala mutant of VP16. Virus strain SJO2 was
constructed with an alanine codon replacing serine codon 375. HeLa cells
infected with KOS or SJO2 were radiolabeled, and the VP16 proteins were
immunoprecipitated and separated by SDS-PAGE as described in Fig. 1. (A)
Autoradiogram, as described in Fig. 1. (B) Immunoblot using VP16-specific
antiserum C8. (C) Autoradiogram of gel-isolated VP16 proteins subjected to
digestion by LysC.samples, suggesting no dramatic change in the level of
phosphorylation of the Ser375Ala version of VP16. Phosphoa-
mino acid analysis (data not shown) indicated that the only
radiolabeled amino acid in the SJO2 VP16 sample was
phosphoserine, indicating that the Ser375Ala mutation did
not shift phosphorylation to an alternative amino acid (such as
the adjacent Thr376). The digestion of both the KOS and the
SJO2 samples by LysC gave rise to a band of an apparent
molecular weight of 17 kDa (Fig. 4C). Again, the intensities of
these peptide signals were similar between the two samples.
From this experiment, we conclude that Ser375 is not
necessary for phosphorylation of VP16 and Ser375 is not a
major site of phosphorylation at late times in infection.
Since Ser375 has been implicated in processes required for
IE gene expression, it was possible that the loss of the site
would cause alteration in expression of these genes, regardless
of phosphorylation status. To examine the hypothesis that
mutation of Ser375 would diminish the VP16-mediated
activation of the IE genes and would thereby result in a
reduction in virus viability, the growth kinetics of SJO2 were
examined. Fig. 5A shows that the yield of progeny virus
following high-multiplicity infection by SJO2 was reduced by
approximately 10-fold relative to infection by the wild-type
virus KOS. Given this modest impact on viral replication, we
considered the possibility that the Ser375Ala missense muta-
tion may be hypomorphic, and thus, its effect might be
suppressed by the exaggerated VP16 concentration in cells
infected at high multiplicity. A comparable defect in yield of
infectious virus was observed following low-multiplicity
infection (Fig. 5B). We conclude that the Ser375Ala mutation
in VP16 affects the yield of infectious virus in a manner
unaffected by multiplicity.
The mutation of Ser375 to Ala likely affects viral replication
because of reduced IE gene expression arising from defective
interaction of VP16 with Oct-1. This hypothesis is based on
evidence of reduced promoter binding in vitro and decreased
activation of IE gene promoters when VP16-Ser375Ala is
expressed by transfection (O’Reilly et al., 1997). Therefore, we
tested both the expression of IE genes and the association of
VP16 with IE gene promoters during HSV infection by SJO2.
Expression of viral IE genes in HeLa cells infected by KOS,
SJO2 or RP5 was measured using quantitative real-time RT-
PCR assays. In Fig. 6, the expression of each IE gene transcript
during infection by the mutant viruses is depicted relative to the
expression detected in KOS infection. These results clearly
indicate a dramatic defect in expression of all IE genes at 2 hpi
during SJO2 infection, in some instances as severe as the
complete deletion of the VP16 activation domain (RP5). The
defect in IE gene expression in SJO2 infection is not quite as
severe at 4 hpi (depicted in Fig. 6B), suggesting that IE gene
expression in SJO2 infection exceeds that in RP5 infection and
perhaps accounting for the less dramatic effect on viral growth
kinetics. We conclude that the mutation of Ser375 to Ala
profoundly affects the ability of VP16 to activate viral IE genes
during lytic infection.
Control experiments ruled out several potential alternative
explanations for the reduced expression levels of IE mRNAs in
Fig. 6. Immediate-early gene expression following infection by HSV-1 strains
KOS, SJO2 and RP5. HeLa cells were infected at a multiplicity of 1 pfu/cell
(KOS) or a corresponding number of virions (SJO2, RP5). RNAwas harvested
at 2 hpi (A) or 4 hpi (B). IE gene expression was assayed by quantitative real-
time PCR following reverse transcriptase reactions. Expression levels were
normalized to 18S rRNAs amplified in parallel Q-PCR reactions and are
expressed relative to the levels observed in KOS infection. Error bars represent
the range of two biological replicates each measured in duplicate PCRs.
Fig. 5. Growth curves of SJO2 and KOS. (A) Vero cells were infected at high
multiplicity (10 pfu/cell) with KOS or SJO2. At 4-h intervals, infected cells
were lysed into the growth medium by scraping and sonication. Following
centrifugation to remove cell debris, aliquots of the resulting supernatant were
tittered on Vero cells. (B) Vero cells were infected with KOS or SJO2 at low
multiplicity (0.01 pfu/cell) and harvested at 12-h intervals. Graphs represent the
average of two biological replicates, which showed a range of less than 20% at
every timepoint.
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sion were observed when parallel experiments were performed
in the presence of cycloheximide (Fig. 7A), indicating that the
reduced levels are not a consequence of IE protein activity and
thus are likely a direct effect of the VP16 mutation. Moreover,
the effects of the SJO2 mutation were completely suppressed
by biochemical complementation with wild-type VP16 protein
(Fig. 7B) that was incorporated into virions of virus strain
SJO2 grown in 16-8 cells, which carry a wild-type VP16 gene
(Tal-Singer et al., 1999; Weinheimer et al., 1992). This result
indicates that no spurious mutation in the SJO2 genome is
likely to be responsible for its defects in IE gene activation.
Gel-shift experiments assessing the in vitro binding of VP16,
Oct-1 and HCF to radiolabeled DNA fragments have indicated
that the Ser375Ala mutation prevents the association of VP16
with Oct-1 and thus disrupts formation of the VP16-induced
complex on the TAATGARAT elements of IE gene promoters
(O’Reilly et al., 1997). To test directly whether the Ser375Ala
mutation affects the association of VP16 and Oct-1 with IEpromoters during lytic infection, we performed cross-linking
and immunoprecipitation experiments. We have previously
described the use of chromatin immunoprecipitation assays to
detect VP16 and Oct-1 proteins at IE gene promoters during
infection by the wild-type virus strain KOS (Herrera and
Triezenberg, 2004). Two hours after HeLa cells were infected
with KOS or SJO2, formaldehyde was added to the culture
medium to cross-link proteins and DNA. Cell nuclei were
harvested and then sonicated to shear the DNA to fragment sizes
primarily within the range of 300 to 500 bp. Samples of the
lysates were then immunoprecipitated with antibodies specific
to VP16 or to Oct-1. After the IP pellets were resuspended, the
cross-links were reversed by incubation at 60 -C. Quantitative
real-time PCR assays were used to measure the amount of the
ICP0 and ICP27 promoter DNA present in each immunopre-
cipitate. The VP16 promoter was assayed as a negative control,
since neither VP16 nor Oct-1 should bind there. The cellular U3
snRNA promoter was used as a positive control for Oct-1
binding. Fig. 8A indicates that immunoprecipitation of VP16
brought down much less of the IE promoters from SJO2-
infected cells than from KOS-infected cells. This observation is
consistent with the hypothesis that Ser375 is important for the
interaction of VP16 with Oct-1 and thus with IE promoter
sequences during lytic infection. Surprisingly, the association of
Oct-1 with IE gene promoters was also markedly reduced in
SJO2-infected cells (Fig. 8B). The presence of Oct-1 at the U3
snRNA promoter was at least as strong in the SJO2 infection as
Fig. 7. Immediate-early gene expression in cells infected with HSV-1 strains KOS and SJO2. (A) HeLa cells were infected with KOS (open bars) or SJO2 (hatched
bars) in the presence or absence of cycloheximide (CHX). Total cellular RNA was harvested at 2 hpi and IE mRNA levels were assayed by quantitative real-time
PCR as in Fig. 6. (B) HeLa cells were infected with KOS (open bars), SJO2 (hatched bars) or SJO2 virions produced in 16-8 cells (filled bars). IE mRNA levels were
assayed as in Fig. 6.
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reactions occurred with comparable efficiency. We conclude
that the occupancy of viral IE promoters by both VP16 and Oct-
1 depends on the interaction of these two proteins, and that this
interaction is disrupted by the Ser375Ala mutation. One
possible explanation for this outcome is that the Ser375Ala
mutation might affect some step of the infection process prior to
the delivery of viral DNA to the nucleus of infected cells. To test
this hypothesis, parallel ChIP assays were performed using an
antibody that recognizes an epitope in the carboxyl terminus of
histone H3. Comparable levels of gC promoter DNA were
found in the H3 IP pellets for KOS and SJO2 infection, whereas
significantly less of the ICP0 promoter DNA was found in the
KOS sample (Fig. 8C). This result is consistent with our
previous observation that VP16 is responsible for a diminished
presence of H3 at IE promoters (Herrera and Triezenberg,
2004). Moreover, the amounts of viral DNA in the infected cell
nuclei were comparable for the KOS and SJO2 infections (Fig.
8D), confirming that the mutant virus was fully capable of
delivering viral DNA prior to IE gene expression.
Mutation of Ser411 has little effect on IE gene regulation or
virus growth
The phosphopeptide mapping of VP16, and particularly the
radiolabeling observed for the LysC fragment of the truncated
protein produced in RP5 infection, pointed to Ser411 as a site
of phosphorylation, but this suggestion was neither supported
nor refuted by the MS/MS results. To test whether Ser411 has a
significant biological role in HSV infection, a viral strain
(designated SO11) was constructed bearing an alanine substi-
tution at this position. To facilitate the identification of the
recombinant virus strains, an enhanced green fluorescent
protein (EGFP) tag was added to the C-terminus of VP16 in
this virus as in a counterpart wild-type virus designated DG1
(Greensides, 2000). The EGFP-tag had no negative effect on
the growth of DG1, nor on a comparable virus constructed in
the O’Hare laboratory (La Boissiere et al., 2004). To examinewhether the Ser411Ala mutation in SO11 affected phosphor-
ylation of VP16, [32P]-labeled VP16 was isolated from HeLa
cells infected with KOS, SO11 and DG1. As expected, a 65
kDa [32P]-labeled band was detected in the KOS sample and a
110 kDa labeled band (representing the VP16-GFP fusion
protein) was detected in the DG1 and SO11 samples (Fig. 9A).
An immunoblot verified the identity of the protein in all three
samples (Fig. 9B). This result demonstrated that the EGFP-tag
did not abolish phosphorylation of VP16. Moreover, the
Ser411Ala mutation did not result in the loss of phosphoryla-
tion of VP16. Growth kinetics following infection by SO11
also did not differ significantly from those observed for KOS
(data not shown). Modest changes in the expression of IE
genes were observed following SO11 infection (Fig. 6A).
Specifically, the steady-state RNA levels for ICP0, ICP4,
ICP27 andICP47 were reduced to 60–70% of the levels
observed in wild-type infections, whereas the level of ICP22
mRNA was elevated by about 50%. These results indicate that
Ser 411 is not a dominant site of phosphorylation and that the
role of Ser411 in regulating IE gene expression, while
detectable, has no substantial effect on lytic replication.
Discussion
Sites of VP16 phosphorylation at late times post-infection
The results reported here reveal several previously unknown
aspects of the phosphorylation of VP16 in infected cells at late
time in HSV-1 infection. Phosphoamino acid analysis indicated
that Ser is the predominant phosphoamino acid in VP16, with
no detectable phosphorylation at Thr or Tyr. Three phosphor-
ylation sites (Ser18, Ser353 and Ser452) were identified by
mass spectrometry; a fourth site (Ser411) implicated by peptide
mapping was neither confirmed nor refuted by mass spectrom-
etry. None of these four sites have been previously implicated
in VP16 phosphorylation. Computer programs designed to
predict phosphorylation sites were more or less consistent with
these observations. NetPhos 2.0 (http://www.cbs.dtu.dk/
Fig. 9. Phosphorylation of a Ser411Ala mutant of VP16. Virus strain DG1
contains a VP16 gene fused to sequences encoding green fluorescent protein
(GFP). SO11 was constructed with an alanine codon replacing serine codon
411, in the DG1 genetic background. HeLa cells infected with KOS, DG1 or
SO11 were radiolabeled, and the VP16 proteins were immunoprecipitated and
separated by SDS-PAGE as described in Fig. 1. (A) Autoradiogram, as
described in Fig. 1. (B) Immunoblot using VP16-specific antiserum C8.
Fig. 8. Association of VP16 and Oct-1 with IE promoters during infection by
HSV-1 strains KOS and SJO2. At 2 h post-infection, proteins and nucleic acids
were cross-linked by formaldehyde. Nuclei were isolated and sonicated to shear
DNA to small fragments (predominantly 300–500 bp). Immunoprecipitation
by antibodies specific to VP16 (A), Oct-1 (B) or H3 (C) was followed by
quantitative real-time PCR to detect DNA fragments corresponding to IE gene
promoters (ICP0 and ICP27), a late gene promoter (VP16 or gC) and a cellular
promoter with an Oct-1 binding site (U3 snRNA). For panels A and B, the
abundance of a given DNA in the IP pellet is indicated relative to its abundance
in a control precipitation without antibody. For panel C, the abundance of a
given DNA in the IP pellet is indicated relative to its abundance in input DNA
(prior to IP). The amounts of viral DNA in nuclear DNA preparations from
infected cells were assessed using quantitative PCR with primers specific for
the VP16 gene (D), normalized to cellular DNA fragments from the U3 and
IFN-h promoters and expressed relative to levels in wild-type-infected cells.
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sites in VP16, but the prediction values for these four sites did
not stand out markedly from others for which we observed no
phosphorylation. When the DISPHOS program {http://core.
ist.temple.edu/pred/pred.html; (Iakoucheva et al., 2004)} was
used with a human regulatory protein training set, three of
these sites (Ser18, 411 and 452) were picked out and a fourth
(Ser353) fell just below the threshold. However, this program
also predicted phosphorylation of Thr31 and Thr458, which
was not supported by our observations.
The amino acid sequences surrounding Ser18 and Ser452
are remarkably similar (ADGASPPPP and GDGDSPSPE,
respectively), suggesting that they might be modified by the
same protein kinase. Ser353 is also followed by Pro, but the
other flanking residues show little similarity to the first sitesmentioned. All three of these SP sites are consistent with the
consensus sequence for phosphorylation by kinases in the JNK
family. Modification by JNKs can facilitate binding of Pin1
prolylisomerases and thus conformational (and potentially
functional) changes in the protein. The amino acid sequence
surrounding Ser411 (TRRLSTAPP) resembles the consensus
sites for modification by the RSK kinase family (Leighton et
al., 1995) or by MSK kinases {reviewed in Roux and Blenis,
2004}. In vitro experiments to identify the kinase(s) respon-
sible for phosphorylating VP16 have yielded conflicting
results. One report indicated that casein kinase II (CKII) could
modify bacterially expressed VP16 polypeptides, and that this
modification was abolished by the mutation of Ser375 to
alanine (O’Reilly et al., 1997). We have also observed
phosphorylation of recombinant VP16 by CKII in vitro,
although in our hands mutation of Ser375 had no quantitative
effect on that reaction (SO, unpublished results). In contrast,
VP16 protein isolated from virions was not phosphorylated in
vitro by CKII but was modified by protein kinase A (although
the site of that modification was not defined) (Morrison et al.,
1998a, 1998b). One hypothesis that might reconcile these
observations is that virion-borne VP16 may be already
phosphorylated at CKII sites and thus refractory to subsequent
modification by CKII.
Using the presently described methods, we were unable to
identify sites of phosphorylation of VP16 during the
immediate-early stage of infection when VP16 activates
transcription of IE genes. The lack of detection might reflect
a lack or low levels of active phosphorylation of VP16 at IE
times, perhaps because virion-borne VP16 is already phos-
phorylated and thus refractory to further modification.
Alternatively, this negative observation may arise from
insufficient sensitivity of the metabolic labeling methods that
we employed. Others have reported that VP16 can be
phosphorylated in infected cells, but those experiments
employed very high infection multiplicities (50 pfu/cell) in
the presence of cycloheximide and the sites of this modifica-
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Chemical inhibitors (e.g., roscovitine) of cellular protein
kinases can dramatically inhibit viral IE and E gene
expression (Jordan et al., 1999; Schang et al., 2002; Schang
et al., 1999), but the relevant direct targets of those kinases
have not been identified. Thus, the phosphorylation status of
VP16 (and specifically Ser375) at IE times of infection
remains unresolved.
Potential functions of VP16 phosphorylation sites
None of the four phosphorylation sites identified in this
work have been previously implicated in any function of VP16.
None of them are highly conserved within the herpes homologs
and no mutations of these sites have been seen in forward or
reverse genetic screens. But the sites may still offer clues to
their function.
Ser18 resides within an N-terminal domain that is dispens-
able for both transcriptional activation and for VIC formation
(Babb et al., 2001; Greaves and O’Hare, 1990; Triezenberg et
al., 1988a, 1988b; Werstuck and Capone, 1989). The amino
acid sequence in this region is poorly conserved among
alphaherpesvirus homologs of VP16, with a corresponding
SerPro dipeptide evident only in the HSV-2 VP16 protein
(Cress and Triezenberg, 1991a). When fused to a Gal4 DNA-
binding domain, this region of VP16 displayed modest ability
to activate transcription, although the residues most important
for that activity include Leu8 and Phe9, some distance from
Ser18 (Moriuchi et al., 1995). Thus, at present, no clear
function can be ascribed to Ser18 or its phosphorylation.
Ser353 resides near a region of VP16 implicated in
interaction with HCF-1 (Lai and Herr, 1997; Shaw et al.,
1995; Simmen et al., 1997; Wu et al., 1994). This region was
not well ordered in the crystallographic structure of the VP16
core polypeptide {aa 49–410; Ref. (Liu et al., 1999)}. The
heart of the HCF-binding motif encompasses amino acids
361–365 (EHAY) (Lai and Herr, 1997; Simmen et al., 1997;
Wu et al., 1994). The associations of two human proteins
with HCF-1, Luman and Zhangfei, depend on very similar
motifs (Freiman and Herr, 1997; Lu and Misra, 2000; Lu et
al., 1998). Using the HCF-1 binding motif as a landmark, the
sequence including Ser353 of VP16 (FTTS) aligns well with
both Zhangfei (LTTS) and Luman (LSSS), such that the
expanded HCF-1 interaction region may have a consensus
sequence A-S/T-S/T-S-X7–8-E/D-H-X-Y, where A denotes a
bulky hydrophobic amino acid. Mutations within the E/D-H-
x-Y motif of these three proteins disrupt interaction with
HCF, but Ser353 and its neighboring residues have not been
similarly tested. Nonetheless, this proximity suggests that
phosphorylation of Ser353 may influence the binding ofVP16
to HCF-1.
Ser411 is not well conserved among VP16 homologs, with
corresponding Ser residues evident only in the proteins from
HSV-2 and perhaps pseudorabies virus. This residue lies in
the very C-terminus of the polypeptide used for crystalliza-
tion of the core domain and was not well ordered in the
resulting structure (Liu et al., 1999). Ser411 also marks theN-terminal boundary of what is considered the canonical
activation domain of VP16. The segment of VP16 encom-
passing Ser411 may be an inert linker between the DNA
binding core domain and the activation domain of VP16.
This residue has not been implicated in important functions
of VP16 by any prior mutational analysis. Our results using a
Ser411Ala mutant virus (SO11) revealed no significant
changes in phosphorylation or viral growth kinetics and
modest effects on IE gene expression. Thus, phosphorylation
of Ser411 apparently does not play a major regulatory role
during lytic infection.
Ser452 lies between the two subdomains of the VP16
activation region, typically considered to comprise amino acids
412–456 and 450–490 (Regier et al., 1993; Sullivan et al.,
1998; Walker et al., 1993). Although Ser452 may simply be
part of a linker between these two activation subdomains, it is
also conceivable that the relative orientations (and thus the
activities) of the activation subdomains are influenced by
phosphorylation in this linker. To date, no mutational tests of
Ser452 have been reported.
Role of Ser375 in IE gene activation
Ser375 was identified as a site of phosphorylation of VP16
expressed in mammalian cells from transfected plasmids
(O’Reilly et al., 1997). Mutations of this residue diminish the
ability of VP16 to interact with Oct-1, to form the VIC
complex in gel-shift assays, and to activate reporter genes
driven by IE promoters (Greaves and O’Hare, 1990; Lai and
Herr, 1997; O’Reilly et al., 1997). Our peptide mapping and
mass spectrometry data revealed no indication of Ser375
phosphorylation at late times during HSV infection. Moreover,
a mutant VP16 protein with a substitution of alanine for Ser375
showed no differences in phosphorylation levels or patterns.
We conclude that Ser375 is not a significant site for VP16
phosphorylation at late times in infection, when VP16 is
robustly expressed.
Although our results neither support nor refute the
hypothesis that Ser375 may be phosphorylated at IE stages
of infection, they do confirm that Ser375 has an important
role in IE gene activation and Oct-1 interaction. During
infection by the SJO2 virus bearing a Ser375Ala mutation, IE
gene expression was significantly diminished but not abol-
ished as during infection by a virus lacking the VP16
activation domain (RP5). This observation is consistent with
transcriptional defects observed in transfection analyses of
Ser375 mutations (Greaves and O’Hare, 1990; Lai and Herr,
1997; O’Reilly et al., 1997). Thus, the Ser375Ala mutation
may be considered hypomorphic with respect to transcrip-
tional activation. If the Ser375Ala mutation disrupts the
interaction of VP16 with Oct-1 (as discussed below) and thus
abolishes activation through the TAATGARAT cis elements in
IE gene promoters, then the slightly higher levels of IE gene
expression in SJO2 infection compared to RP5 infection
might arise by the residual action of VP16 through other cis
elements such as the GA-rich sequences (LaMarco and
McKnight, 1989; Triezenberg et al., 1988a, 1988b). This
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expression is not abolished upon high-multiplicity infection
of Oct-1-deficient mouse cells (Nogueira et al., 2004).
In vitro experiments indicated a reduced ability of the
Ser375Ala mutant form of VP16 to bind to Oct-1 and to
participate in the VP16-induced complex in gel-shift assays
(Greaves and O’Hare, 1990; Lai and Herr, 1997; O’Reilly et al.,
1997). Thus, we were not surprised to find that this mutation
disrupted the ability of VP16 to associate with IE gene promoters
during lytic infection. The levels of IE promoter DNA fragments
that co-immunoprecipitated with VP16 were markedly reduced
in SJO2 infection compared with KOS infection. However, we
were surprised to find that the IE promoter fragments were also
less abundant in the Oct-1 immunoprecipitation pellets, indicat-
ing a reduced occupancy of these promoters by Oct-1 as well as
by VP16. This observation indicates that the binding of Oct-1 to
DNA at viral IE promoters depends on the interaction of Oct-1
with VP16. Although no such requirement had been revealed
from in vitro gel-shift experiments, there are indications that
VP16 qualitatively alters the interaction of Oct-1 with DNA. For
example, VP16 affects the manner in which Oct-1 binds to
versions of the TAATGARAT element that do or do not have
overlapping consensus octamer motifs (Herr and Cleary, 1995).
The ‘‘GARAT’’ motif also helps dictate specificity for VP16-
containing complexes (Walker et al., 1994). Our new observa-
tions, however, reveal a quantitative effect indicating that, in
vivo, Oct-1 andVP16 together form a novel DNA-binding entity
in which VP16 contributes materially to the binding of Oct-1 to
viral IE promoters.
Presumably as a consequence of the reduced IE expression
levels, the SJO2 virus strain showed comparable 10-fold
reductions in viral growth kinetics following both low- and
high-multiplicity infection (Fig. 5). The diminished growth
curves for SJO2 likely arise from defects in infectivity of the
progeny virions, since the yield of viral proteins and DNA
(detected by Western blots and quantitative PCR, respectively;
data not shown) did not differ significantly from those
observed for wild-type viruses. In contrast, other VP16 mutant
viruses, including the RP5 strain lacking the VP16AD
altogether, show a much greater defect following low-
multiplicity infection (Ace et al., 1989; Smiley and Duncan,
1997; Tal-Singer et al., 1999). Perhaps the difference in growth
kinetics between SJO2 and RP5 at low-multiplicity arises not
solely from the modest difference in the abilities of these
viruses to activate IE gene expression but from some non-
transcriptional function of the VP16AD (e.g., interaction with
VP22) that affects the infectivity of the virus.
Our present results do not fully address the question of
whether Ser375 phosphorylation per se affects the interaction
of VP16 with Oct-1 and the subsequent impact of that effect on
IE gene regulation during infection. It may be that the
transcriptionally active form of VP16 is phosphorylated at
Ser375, and that the lack of phosphorylation at Ser375 late in
infection might represent a down-regulation of that function of
VP16. More sensitive assays, perhaps using antibodies
specifically recognizing a phosphoserine 375 epitope, will be
required to resolve this matter.Materials and methods
Cells and viruses
HeLa and Vero cells obtained from the American Type
Culture Collection were grown in Dulbecco’s modified Eagle’s
medium (DMEM; Gibco) supplemented with 3.7 g/l sodium
bicarbonate and 10% fetal calf serum (FCS; Select fetal calf
serum, Atlanta Biologicals). Vero-16-8 cells (Weinheimer et
al., 1992) and BHK-MMTV-VP16 cells (Hippenmeyer and
Highkin, 1993) express integrated copies of the wild-type
VP16 gene and were used for complementation of defective
virus strains. Vero-16-8 cells and BHK-MMTV-VP16 cells
were grown in DMEM with FCS in the presence of Geneticin
at 0.9 or 0.5 Ag/ml respectively to maintain selection for the
transgene.
Viral stocks were generated in Vero cells or Vero-16-8 cells.
Titers of all stocks were determined by plaque assays on Vero
cells. The HSV-1 strain KOS was the wild-type strain used in
this study. The 8MA, RP3, RP5 and DG1 strains are
derivatives of KOS. In 8MA, the VP16 ORF was replaced
with the LacZ gene (Weinheimer et al., 1992). The RP3 and
RP5 strains carry a truncated VP16 gene comprising codons 1–
454 and 1–413, respectively (Tal-Singer et al., 1999). Strain
DG1 expresses full-length wild-type VP16 fused at its carboxyl
terminus to the enhanced green fluorescent protein (EGFP) (D.
Greensides and SJT, unpublished). A virus strain expressing a
similar VP16-GFP fusion has been recently described by others
(La Boissiere et al., 2004).
Several additional recombinant viruses were derived from
KOS for the purposes of this study, essentially as described
previously (Tal-Singer et al., 1999). PCR-mediated site-
directed mutagenesis was used to generate specific codon
substitutions in plasmid pKOS-VP16.2. Mutagenic primer
sequences are available upon request. XhoI-PstI restriction
fragments bearing the VP16 coding sequences from mutant
plasmids were co-transfected with genomic DNA from the
VP16-null virus strain 8MA into Vero-16-8 or BHK-MMTV-
VP16 cells. Recombinant virus strains were isolated through
three rounds of plaque purification. For each strain, the
mutation identity was confirmed by PCR amplification of a
VP16 gene fragment analyzed for loss of an AccI site at codon
375 or 411, respectively, and then by direct DNA sequencing.
Strain SJO2 expresses VP16 altered by a Ser375Ala mutation.
Strain SO11 expresses a Ser411Ala mutant of VP16 with a
carboxyl terminal EGFP fusion.
To determine growth curves of various virus strains, Vero
cells were plated at a density of 2105 cells per 60 mm tissue
culture plate. After 24 h, cells were infected with virus at an
MOI of 10 (for single-step growth curves) or 0.01 (for
multiple-step growth curves). Duplicate samples were har-
vested at 4-h intervals (for single-step growth curves) or 12-
h intervals (for multiple-step growth curves). The samples were
harvested by dislodging cells into the overlying medium with a
disposable scraper. The cells were disrupted by sonication, and
insoluble cell debris was removed by centrifugation. The titer
of each sample was determined in triplicate by plaque assay.
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LP1, a monoclonal antibody that recognizes an epitope near
the amino terminus of VP16 (McLean et al., 1982), was
generously provided by A. Minson and was used for
immunoprecipitation of VP16 from infected cell extracts. C8
and LA2–3 are rabbit polyclonal antisera. C8 was raised
against VP16 purified from virions (Triezenberg et al., 1988a,
1988b). LA2–3 was raised against the bacterially expressed
fusion protein Gal4VP16 and recognizes epitopes both within
the Gal4 DNA-binding domain and the VP16 transcriptional
activation domain (amino acids 410–490) (Sullivan et al.,
1998). A rabbit polyclonal antiserum recognizing the human
Oct-1 protein was a gift from Dr. Winship Herr, Cold Spring
Harbor Laboratory.
Immunoblots
Wild-type or mutant VP16 proteins were detected in
immunoblots using the rabbit polyclonal antisera LA2–3 or
C8. Protein samples were separated by SDS-PAGE using either
Laemmli buffer (10% polyacrylamide gels) or a Tris–Tricine
buffer (16.5% polyacrylamide gels) and then electrophoreti-
cally transferred to nitrocellulose. The membrane was blocked
for 1 h at ambient temperature under constant agitation with
10% non-fat dry milk in T-TBS (125 mM Tris, pH 7.5, 1.5 M
sodium chloride, 0.1% Tween 20). The blot was then incubated
for 1 h with the primary antibody diluted in T-TBS
supplemented with 10% calf serum (Gibco). All three
antibodies were diluted 1:10,000 to 1:50,000. The blot was
visualized, using HRP-conjugated goat-anti-rabbit IgG
(BioRad, 172–1013), diluted and incubated as described for
the primary antibody. The bands were visualized using a
chemiluminescence detection system (LumiLight, Roche).
Immunoprecipitation
[32P]-labeled VP16 was isolated from infected cells and
from solubilized virions by immunoprecipitation. HeLa cells
(107 in a 150 cm2 culture flask) were infected with KOS, RP3,
SJO2 or SO11 at a moi of 5–10. Infections with RP5 were
done at a moi of 0.1 in order to compensate for the high
particle-pfu ratio of this strain. After 1 h, the DMEM was
replaced with phosphate-free DMEM supplemented with 2%
dialyzed FCS. After another 30 min, the medium was replaced
with fresh phosphate-free DMEM supplemented with 2%
dialyzed FCS and 1 mCi of [32P]-orthophosphate (NEN:
specific activity 285 Ci/mg) was added.
VP16 was isolated from infected cell lysates at 8 hpi or from
virions isolated at 14 hpi. For lysates, infected cells were
scraped from the culture dish and collected by centrifugation.
Cell pellets were resuspended in 500 Al of IP lysis buffer {50
mM Tris–HCl, pH 7.5, 150 mM NaCl, 0.1% SDS, 1.0%
sodium deoxycholate, 1.0% Triton X-100, 2 mM phenyl-
methylsulfonylfluoride, 1 COMPLETE protease inhibitor
mix (Roche)}, incubated on ice for 30 min and then disrupted
using a cup horn sonicator. Cellular debris was removed bycentrifugation. Virions were isolated at 14 hpi by collecting
infected cells along with the growth medium. Cells were
disrupted by sonication and debris removed by centrifugation
at 3000  g for 5 min. The supernatant containing the virions
was centrifuged through a 20% glycerol cushion for 90 min at
130,000  g. The pelleted virions were resuspended in 500
Al of IP lysis buffer.
Infected cell lysates and virion extracts were precleared by
adding 100 Al of a 10% suspension of heat-killed, formalin-
fixed Staphylococcus aureus (SAC). The samples were
incubated for 3 h at 4 -C with constant agitation and then
centrifuged for 10 min at 16,000  g at 4 -C. Five microliters
of the monoclonal antibody LP1 was added to the supernatant,
and the samples were incubated for 1 h at 4 -C with constant
agitation. Fifty microliters of SAC was then added, and the
incubation continued for another 2 h. The precipitates were
collected by centrifugation at 200  g for 2 min. The pellets
were washed three times in lysis buffer and once briefly in 1
mM phosphate buffer, pH 8. The bound VP16 was then eluted
using 50 Al of 10 mM phosphate buffer at pH 12.5 which was
subsequently neutralized with 20 Al of 100 mM phosphate
buffer, pH 6.8.
Peptide mapping
Immunoprecipitated [32P]-labeled VP16 isolated from
infected HeLa cells at 8 hpi was separated on a 10% SDS-
PAGE gel. The migration of the labeled VP16 species was
determined by autoradiography of the wet gel. The
corresponding band was excised from the gel and then washed
twice in 0.1 M ammonium carbonate, 50% acetonitrile for 50
min at 30 -C. The gel slice was dried under a nitrogen stream
and then was rehydrated with 4 Al of 0.1 M ammonium
carbonate, pH 7.5, 0.02% Tween 20. Immediately thereafter, 1
Al of digestion buffer with either 2 Ag of trypsin or
endolysylpeptidase C was added. The sample was digested
overnight at 30 -C. The protein was eluted from the gel slice by
gentle sonication and was then separated on a 16.5% Tris–
Tricine SDS-PAGE gel. The gel was then either transferred to
nitrocellulose or soaked in several washes of 10% methanol/
7% acetic acid and dried onto Whatman 3 MM paper. The
labeled protein on either the membrane or the dried gel was
visualized by autoradiography.
Phosphoaminoacid analysis
Immunoprecipitated [32P]-labeled VP16 isolated from
infected HeLa cells at 8 hpi was separated on a 10% SDS-
PAGE gel and electrophoretically transferred to a PVDF
membrane. The labeled species corresponding to VP16 was
identified by autoradiography. The corresponding PVDF
fragment was excised and digested in 6N hydrochloric acid
for 1 h at 100 -C. The sample was dried and mixed with
phosphoamino acid standards (2 Ag each in 5 Al) and then
spotted on a cellulose thin-layer electrophoresis plate. Follow-
ing electrophoresis at 500 V for 1 h at pH 2.5, the plate was
dried and sprayed with ninhydrin (0.5% in acetone), then
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radiolabeled amino acids were visualized by autoradiography.
Mass spectrometry
Unlabeled VP16 was immunoprecipitated from 109 HeLa
cells infected with HSV-1 strain KOS at 8 hpi using the method
described above except that no [32P]-orthophosphate was
added and 25 Al of LP1 was used for each sample. Protein
eluted from the immunoprecipitate was separated by electro-
phoresis in a 10% polyacrylamide denaturing gel (SDS-PAGE).
A gel slice corresponding to VP16 (detected by staining with
Coomassie Blue) was washed in acetonitrile, dried and frozen.
Following in-gel digestion by trypsin, chymotrypsin and
endoproteinase AspN, sequence analysis of proteolytic frag-
ments was performed by microcapillary reverse-phase HPLC
nano-electrospray tandem mass spectrometry (ALC/MS/MS)
on a Finnigan LCQ DECA XP Plus quadrupole ion trap mass
spectrometer.
Gene expression assays
Steady-state levels of viral mRNAs were determined using
quantitative reverse-transcriptase PCR assays (qRT-PCR).
Total RNA was isolated from approximately 2106 infected
HeLa cells at 2 or 4 h post-infection using TRI-Reagent
(Molecular Research Center). cDNA was prepared using 1 Ag
total RNA and a randomly primed reverse transcription system
(Promega). Viral or cellular gene fragments (Table 2) were
amplified using SYBR Green Core reagents and ABI Prism
7700 (Applied Biosystems). PCR conditions included 0.1–
0.25 AM each primer, 2–3 mM MgCl2 and 0.75 U Taq DNA
polymerase (Applied Biosystems) in 30 Al final volume.Table 2
Oligonucleotides used as primers in quantitative real-time PCR to detect viral imm
Gene Class Region Oli
ICP0 IE P (F)
(R)
ORF (F)
(R)
ICP4 IE ORF (F)
(R)
ICP22 IE ORF (F)
(R)
ICP27 IE P (F)
(R)
ORF (F)
(R)
ICP47a IE ORF (F)
(R)
VP16 L P (F)
(R)
U3 snRNA C P (F)
(R)
18S rRNA C (F)
(R)
The orientations of the primers are indicated relative to the transcription unit (F for fo
start site (+1) of each gene.
a The ICP47 primer overlaps with the US11 transcript. At early times of infectionsRelative levels of viral gene expression were obtained by the
2-DDCt method (Livak and Schmittgen, 2001) using wild-type
infections as standard and 18S rRNA as endogenous control.
Bars represent the average expression levels of two or three
independent infections each measured in duplicate. Errors bars
indicate the range of the biological triplicates.
Chemical cross-linking and immunoprecipitation assays
Chromatin immunoprecipitation assays (ChIPs) were per-
formed as described previously (Herrera and Triezenberg,
2004). In brief, HeLa cells (approximately 3107 cells) were
infected with wild-type HSV-1 (KOS strain) or SJO2 strain at a
multiplicity of 5 pfu/cell. Two hours after infection, protein–
DNA complexes were cross-linked by adding formaldehyde to
the medium overlaying infected cells to a final concentration of
1%. Chromatin was prepared and sonicated to obtain DNA
fragments with an average length of 300–400 bp. Immuno-
precipitations were performed using specific antibodies direct-
ed against VP16 (C8-5), Oct-1 (#143, a gift from W. Herr, Cold
Spring Harbor Laboratory) and histone H3 (ab1791, Abcam),
using concentrations of approximately 50 Ag/ml at 4 -C
overnight. Antigen–antibody complexes were precipitated
using protein-G agarose beads (Upstate). The beads were
washed extensively before protein–DNA complexes were
eluted. Cross-links were reversed, and samples were subse-
quently digested with proteinase K (Boehringer). The DNA
was purified using QIAquick PCR Purification Kit (QIAGEN)
and resuspended in 75 Al TE pH 8.0. Quantitative polymerase
chain reactions (qPCRs) were performed to detect specific viral
or cellular gene fragments in the immunoprecipitated samples
(Table 2). qPCRs were performed on a ABI Prism 7700
Sequence Detection System using SYBR Green Core Reagentsediate early (IE), late (L), or cellular (C) gene fragments
gonucleotide sequence PCR endpoints
5V-GGCCGTGCATGCTAATGATA
5V-CTTATACCCCACGCCTTTCC
172 to 20
5V-CTGTCGCCTTACGTGACCAA
5V-CCATGTTTCCCGTCTGGTC
3022 to 3133
5V-GAAGTTGTGGACTGGGAAGG
5V-GTTGCCGTTTATTGCGTCTT
4125 to 4257
5V-TTTGGGGAGTTTGACTGGAC
5V-CAGACACTTGCGGTCTTCTG
1575 to 1712
5V-GTCCCGTTACCAAGACCAAC
5V-GCACAGACAAGGACCAATCA
235 to 102
5V-TGCATCCTTCGTGTTTGTCATTCTGG
5V-GCCGTCAACTCGCAGACACGACTC
1099 to 1249
5V-GTACGACCATCACCCGAGTC
5V-GACGGCACGCCTTTTAAGTA
808 to 935
5V-CAGCCCGCTCCGCTTCTCG
5V-GCCGCCCCGTACCTCGTGAC
272 to 47
5V-GCACCACACCAGGAGCAAAC
5V-CGCTAGTTCCGATGCCATTAGG
295 to 71
5V-CCGCAGCTAGGAATAATGGA
5V-CGGTCCAAGAATTTCACCTC
850 to 975
rward and R for reverse). PCR endpoints are defined relative to the transcription
US11 is not expressed, and thus, this PCR detects ICP47 gene expression levels.
S. Ottosen et al. / Virology 345 (2006) 468–481480(Applied Biosystems). Standard PCR conditions included 3
Al of template (IP or ‘‘No Ab’’ samples), 0.25 AM of each
primer, 0.75 U Taq DNA polymerase (Applied Biosystems)
and 3 mM MgCl2 in 30 Al final volume. The enrichment of a
particular promoter over background levels in the IP reactions
(Relative IP) was obtained by subtracting CT values of ‘‘No
Ab’’ sample from Ct values of a particular IP and using the
formula 2DCt to calculate the fold enrichment. For ChIP
assays using histone H3 antibodies, the presence of specific
DNA in the IP sample is expressed relative to input (pre-IP)
DNA. Viral DNAs in nuclear DNA preparations were
measured by Q-PCR, normalized to cellular DNA fragments
from the U3 and IFN-h promoters and then normalized to wild-
type (KOS) DNA levels. The figures show representative
experiments, with error bars that represent the range of the
technical duplicates.
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